HIG raises $268 million for life sciences fund

Wednesday, April 11, 2012 12:09 PM

HIG BioVentures II, a HIG Capital fund that will invest in a broad range of sectors and development stages with a focus on pharmaceuticals, medical devices and diagnostics, has successfully closed as of March 28.

The fund, which was over-subscribed with total aggregate commitments of $268 million—exceeding its $250 million target—was raised entirely from limited partners specific to HIG BioVentures II. Partners included a diverse group of top-tier global investors, such as public and private pension funds, foundations, funds of funds and large private family wealth managers. The fund will make venture capital investments in innovative, product development focused healthcare companies located throughout North America.

HIG believes the healthcare sector remains highly attractive as a non-discretionary expenditure resistant to economic downturns. Revenues for pharmaceutical, medical device and diagnostics companies will continue to increase, as they drive more efficient healthcare delivery to an aging population with a growing landscape of significant unmet medical needs.

"We are very pleased with this fund, which we believe is the appropriate size to execute our strategy," said Aaron Davidson, managing director of HIG BioVentures. "We are seeing more and higher quality deal flow in the healthcare sector today than at any time in our history. The most effective way to meet the demands of today's evolving and challenging healthcare market is through innovative products that provide significant patient benefit on a cost-effective basis."

HIG BioVentures II will follow the same proven strategy as its predecessor fund, investing in product development and commercial companies with capital efficient business models.  "We are seeking companies with well-defined products and viable business models, including clinical/regulatory, reimbursement, and go-to-market strategies," said Bruce Robertson, managing director of HIG BioVentures.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs